The Latest Breaking News on Pharma

BALTIMORE — As soon as this summer, people will be able to purchase the opioid overdose reversal medication Narcan as easily as they can buy Tylenol and Benadryl, after the U.S. Food and Drug Administration approved it last week to be sold over the counter.

In only four states do residents spend more on drugs than the Land of Lincoln. The health care industry faces a monopoly problem, not a market problem

The actor stars alongside his son (playing his son) in a nauseatingly schmaltzy, second-tier comedy. It’s utterly unfunny, but at least its lead is as charming as ever

The decision comes as a bid to widen access to the life-saving drug as the US struggles with a wave of overdose deaths.

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

Recent expansion created an additional 80 to 100 new scientific and technical jobs at the facility - and now more have been created

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

As March comes to an end, biotech stocks Exelixis (EXEL), MacroGenics (MGNX), and Puma Biotechnology (PBYI) have been losing momentum. However, given the long-term prospects of the biotechnology industry and the administration’s push to boost domestic biomanufacturing, these biotech stocks could prove to be solid long-term investments. Read more.

Pharmacy chiefs have issued a warning over shortages of medicine cabinet essentials like Calpol, Nurofen as demand is higher than previous years - while the supply is lower